Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium
Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3
or KCNQ3) - Pipeline Review, H2 2016
Complete
report details @ https://www.wiseguyreports.com/reports/649745-potassium-voltage-gated-channel-review-h2-2016
Summary
‘Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium
Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3
or KCNQ3) - Pipeline Review, H2 2016’, provides in depth analysis on Potassium
Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha
KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) targeted
pipeline therapeutics.
The report provides comprehensive information on the Potassium
Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha
KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) , targeted
therapeutics, complete with analysis by indications, stage of development,
mechanism of action (MoA), route of administration (RoA) and molecule type. The
report also covers the descriptive pharmacological action of the therapeutics,
its complete research and development history and latest news and press
releases. Additionally, the report provides an overview of key players involved
in Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel
Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3)
targeted therapeutics development and features dormant and discontinued
projects.
Report features investigational drugs from across globe covering
over 20 therapy areas and nearly 3,000 indications. The report is built using
data and information sourced from proprietary databases, company/university
websites, clinical trial registries, conferences, SEC filings, investor
presentations and featured press releases from company/university sites and
industry-specific third party sources. Drug profiles featured in the report
undergoes periodic review following a stringent set of processes to ensure that
all the profiles are updated with the latest set of information. Additionally,
various dynamic tracking processes ensure that the most recent developments are
captured on a real time basis.
The report helps in identifying and tracking emerging players in
the market and their portfolios, enhances decision making capabilities and
helps to create effective counter strategies to gain competitive advantage.
Request
a sample report @https://www.wiseguyreports.com/sample-request/649745-potassium-voltage-gated-channel-review-h2-2016
Scope
- The report provides a snapshot of the global therapeutic
landscape for Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium
Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3
or KCNQ3)
- The report reviews Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) targeted therapeutics and enlists all their major and minor projects
- The report assesses Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) targeted therapeutics
- The report reviews Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) targeted therapeutics and enlists all their major and minor projects
- The report assesses Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) targeted therapeutics
Reasons
to buy
- Gain strategically significant competitor information, analysis,
and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Check Discount on this report @ https://www.wiseguyreports.com/check-discount/649745-potassium-voltage-gated-channel-review-h2-2016
Table of Contents
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) Overview 7
Therapeutics Development 8
Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Products under Development by Stage of Development 8
Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Products under Development by Therapy Area 9
Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Products under Development by Indication 10
Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Products Glance 11
Late Stage Products 11
Early Stage Products 12
Unknown Stage Products 13
Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Products under Development by Companies 14
Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Products under Development by Universities/Institutes 16
Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Therapeutics Assessment 18
Assessment by Monotherapy/Combination Products 18
Assessment by Mechanism of Action 19
Assessment by Route of Administration 20
Assessment by Molecule Type 21
Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Companies Involved in Therapeutics Development 22
1st Order Pharmaceuticals Inc 22
Grunenthal GmbH 23
Saniona AB 24
SciFluor Life Sciences, LLC 25
Valeant Pharmaceuticals International, Inc. 26
Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Drug Profiles 27
1OP-2198 - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
ezogabine - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
NH-34 - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
SF-0034 - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
Small Molecule to Activate Kv7.2 and Kv7.3 Channels for Epilepsy and Pain - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
Small Molecules to Activate KCNQ and TSPO for Pain - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
Small Molecules to Activate KCNQ2 and KCNQ3 Channels for Chronic Pain and CNS disorder - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Discontinued Products 37
Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Featured News & Press Releases 38
Jun 19, 2015: SciFluor Life Sciences Patented Compound SF0034 Highlighted in Research Published in The Journal of Neuroscience 38
Apr 16, 2015: The ALS Association, Harvard Stem Cell Institute, and Massachusetts General Hospital Neurological Clinical Research Institute Collaborate with GlaxoSmithKline on New ALS Clinical Trial 39
Feb 04, 2015: Anti-epilepsy drug preserves brain function after stroke 39
Jan 08, 2015: SciFluor Life Sciences Awarded U.S. Patent for KCNQ2/3 Activator Designed for Treatment of Epilepsy and Related Neurological Disorders 40
Jun 25, 2013: SciFluor Life Sciences Presents New Preclinical Data For SF0034 At 30th International Epilepsy Congress 41
May 31, 2013: EMA's CHMP Recommends Restricting Trobalt To Last-line Therapy In Partial Epilepsy 42
May 27, 2013: Valeant Pharma's Retigabine Shows Promise In Preventing Noise-induced Tinnitus In Animal Model, Pitt Researchers Report 43
Jul 27, 2011: Glaxosmithkline's Drug Retigabine Added To NHS Treatment Options 44
Jun 16, 2011: Retigabine May Further Help People With Epilepsy, NICE Says 44
Jun 13, 2011: Valeant And GlaxoSmithKline Announce FDA Approval For Potiga 45
Apr 18, 2011: GSK And Valeant Respond To FDA On Ezogabine 46
Mar 29, 2011: GSK And Valeant Receive European Authorization For Trobalt 46
Jan 21, 2011: GSK And Valeant Receive Positive Opinion In Europe From CHMP For Trobalt 47
Dec 01, 2010: GSK And Valeant Receive FDA Complete Response Letter For Ezogabine 47
Aug 30, 2010: GSK And Valeant Receive New FDA PDUFA Goal Date For Ezogabine 47
Appendix 48
Methodology 48
Coverage 48
Secondary Research 48
Primary Research 48
Expert Panel Validation 48
Contact Us 48
Disclaimer 49
Contact
US:
NORAH
TRENT
Partner
Relations & Marketing Manager
sales@wiseguyreports.com
Ph:
+1-646-845-9349 (US)
Ph:
+44 208 133 9349 (UK)
No comments:
Post a Comment